Solna, November 30, 2022 – Vivesto AB, an oncology-focused specialty pharma company, announced today that the company's acting CEO Christer Nordstedt will remain in his position part-time until Vivesto's new permanent CEO Erik Kinnman takes up his position.
On November 21, 2022, Vivesto announced that Erik Kinnman was appointed as the new CEO of Vivesto, effective no later than May 20, 2023. Vivesto has today agreed with Christer Nordstedt that he will remain in his current position as acting CEO of Vivesto on a part-time basis until Erik Kinnman takes office.
"We are very pleased that Christer can remain in his role as acting CEO of Vivesto. During the short time he has been with us, Christer has demonstrated his broad competence and long experience from the industry, and we look forward to a seamless transition until Erik Kinnman takes office. It is also gratifying that Christer will continue to contribute to the company's development as a senior advisor in R&D," said Peter Zonabend, Chairman of the Board of Vivesto.
As of December 1, 2022, Christer Nordstedt will also hold the position as CEO of Oblique Therapeutics AB.
For further information:
Peter Zonabend, Chairman of the Board of Vivesto
Phone: +46 18-50 54 40
E-mail: IR@vivesto.com
About Vivesto AB
Vivesto is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. It has a growing pipeline of clinical-stage assets targeting late-stage cancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancer patients through a partnership with Elevar Therapeutics, Inc. Development programs include Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxel micellar, in development for advanced prostate cancer. Vivesto has proprietary drug delivery technology designed to improve solubility, efficacy and safety. Vivesto’s shares are traded on Nasdaq Stockholm (VIVE). To find out more about Vivesto please visit www.vivesto.com.